TABLE III.

Ongoing phase ii/iii studies examining bendamustine combination regimens in relapsed non-Hodgkin lymphoma (nhl)

National Clinical Trials ID number	Phase	Pts (n)	Condition	Treatment arm
NCT01170052	i/ii	20	Mantle cell lymphoma	Bendamustine–temsirolimus
NCT01078142	i/ii	72	Follicular lymphoma, mantle cell lymphoma	Bendamustine–temsirolimus–rituximab
NCT00992134	ii	48	Mantle cell lymphoma	Bendamustine–cytarabine–rituximab
NCT01133158	ii	60	Follicular lymphoma	Bendamustine–mitoxantrone–dexamethasone–rituximab
NCT01127841	ii	60	Follicular lymphoma	Bendamustine–rituximab
NCT01294579	ii	53	Indolent nhl	Bendamustine–ofatumumab
NCT01077518	iii	388	Indolent nhl	Bendamustine–ofatumumab vs. bendamustine
NCT01059630	iii	360	Indolent nhl	Bendamustine–obinutuzumab vs. bendamustine